about
DNA cross-linking by azinomycin B: Monte Carlo simulations in the evaluation of sequence selectivityChalcones: a valid scaffold for monoamine oxidases inhibitorsSelective inhibitory activity against MAO and molecular modeling studies of 2-thiazolylhydrazone derivativesHCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitorsGRID-based three-dimensional pharmacophores II: PharmBench, a benchmark data set for evaluating pharmacophore elucidation methods.Synthesis and selective human monoamine oxidase inhibition of 3-carbonyl, 3-acyl, and 3-carboxyhydrazido coumarin derivatives.Synthesis and biological assessment of novel 2-thiazolylhydrazones and computational analysis of their recognition by monoamine oxidase B.Isolation and functional characterization of peptide agonists of PTPRJ, a tyrosine phosphatase receptor endowed with tumor suppressor activity.Discovery of PTPRJ agonist peptides that effectively inhibit in vitro cancer cell proliferation and tube formation.Identification of new natural DNA G-quadruplex binders selected by a structure-based virtual screening approach.Fhit delocalizes annexin a4 from plasma membrane to cytosol and sensitizes lung cancer cells to paclitaxel.Conformation and stability of intramolecular telomeric G-quadruplexes: sequence effects in the loops.Design, synthesis, and biological evaluation of 1,3-diarylpropenones as dual inhibitors of HIV-1 reverse transcriptase.Incomplete APOBEC3G/F Neutralization by HIV-1 Vif Mutants Facilitates the Genetic Evolution from CCR5 to CXCR4 Usage.Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors.Synthesis, biological evaluation and 3D-QSAR of 1,3,5-trisubstituted-4,5-dihydro-(1H)-pyrazole derivatives as potent and highly selective monoamine oxidase A inhibitors.Effect of the human immunodeficiency virus type 1 reverse transcriptase polymorphism Leu-214 on replication capacity and drug susceptibility.Computational analysis of Human Immunodeficiency Virus (HIV) Type-1 reverse transcriptase crystallographic models based on significant conserved residues found in Highly Active Antiretroviral Therapy (HAART)-treated patients.Molecular and structural aspects of clinically relevant mutations related to the approved non-nucleoside inhibitors of HIV-1 reverse transcriptase.Targeting unimolecular G-quadruplex nucleic acids: a new paradigm for the drug discovery?Macrocyclic naphthalene diimides as G-quadruplex binders.SI113, a specific inhibitor of the Sgk1 kinase activity that counteracts cancer cell proliferation.In silico identification and biological evaluation of novel selective serum/glucocorticoid-inducible kinase 1 inhibitors based on the pyrazolo-pyrimidine scaffold.Structure-activity relationships of novel substituted naphthalene diimides as anticancer agents.Hybrid ligand-alkylating agents targeting telomeric G-quadruplex structures.State-of-the-art and dissemination of computational tools for drug-design purposes: a survey among Italian academics and industrial institutions.Effect of maraviroc on non-R5 tropic HIV-1: refined analysis of subjects from the phase IIb study A4001029.3-Acetyl-2,5-diaryl-2,3-dihydro-1,3,4-oxadiazoles: a new scaffold for the selective inhibition of monoamine oxidase B.Synthesis of new 3-aryl-4,5-dihydropyrazole-1-carbothioamide derivatives. An investigation on their ability to inhibit monoamine oxidase.Hit identification and biological evaluation of anticancer pyrazolopyrimidines endowed with anti-inflammatory activity.Rational design, synthesis, biophysical and antiproliferative evaluation of fluorenone derivatives with DNA G-quadruplex binding properties.Dependence of DNA sequence selectivity and cell cytotoxicity on azinomycin A and B epoxyamide stereochemistry.Design and synthesis of DNA-intercalating 9-fluoren-beta-O-glycosides as potential IFN-inducers, and antiviral and cytostatic agents.Bioactive compounds of Crocus sativus L. and their semi-synthetic derivatives as promising anti-Helicobacter pylori, anti-malarial and anti-leishmanial agents.Methoxyflavones from Stachys glutinosa with binding affinity to opioid receptors: in silico, in vitro, and in vivo studies.(3Z)-3-(2-[4-(aryl)-1,3-thiazol-2-yl]hydrazin-1-ylidene)-2,3-dihydro-1H-indol-2-one derivatives as dual inhibitors of HIV-1 reverse transcriptase.Chromone, a privileged scaffold for the development of monoamine oxidase inhibitors.Homoisoflavonoids: natural scaffolds with potent and selective monoamine oxidase-B inhibition properties.Synthesis and molecular modelling studies of prenylated pyrazolines as MAO-B inhibitors.Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors.
P50
Q28217764-F18EF87B-F3F4-4DAC-9306-51BBD430ABACQ28241873-2B059007-80A0-4FC6-A40A-46EF95F53B17Q28285054-E17899D2-8726-40BC-9F37-1C84BA19693DQ28481038-0F6CA5F5-ECDF-4F3A-842E-FE9215599353Q30564462-C517382D-4661-4841-9B67-C31D9B0CCF13Q34004214-FECC9DF3-46FB-458E-B863-353AC08DC4D1Q34119721-D3BB222B-EF7D-4456-8DCD-070386B7D0B6Q34324528-2EE730AA-2472-4550-B43F-C0488EB12449Q34693841-5E8DCAE1-E7EC-4AEF-A042-041999834608Q35003819-D534AD44-3E93-4D36-9AFB-A17A56A45F8AQ35040216-030CB3DF-C116-4337-9407-9E74FA34ABA7Q35075676-CC4486D0-1A60-492B-AE95-BE755360040EQ35172317-B3F90BCD-1E06-4BBD-8354-87C74924C315Q35859926-98CC364F-2E30-4C49-AF25-C289C3385D08Q36099251-3E3D87ED-2072-41D5-9C67-01BA5D394901Q36486172-CB8049E8-67FF-49C4-A878-A726A0139459Q37256719-A3B6A302-DCC9-41B2-BB7D-D6D75FA818C4Q37656453-B5AAABF6-EB79-4A41-9518-6D74D872CA91Q37835977-13CC8FF0-4CEC-4212-92E4-D4BA532B365AQ38238562-3F225440-5D8E-4998-B042-D2FEFB40BD0FQ38879843-B508C1E1-D3A3-4F9A-8CF5-BADF911E3BD6Q38887535-ABA73B67-8CCB-427A-94C2-6D3CCB479211Q38988436-C68938F3-DC2E-4498-86C9-4FC0CDC554B2Q39310834-F9B99C16-0846-48DC-9A8D-E2B1F3965180Q39389811-F4075F83-BDE3-4AAD-B856-7FF63DA59274Q39417388-282FA227-8550-494A-8805-B1EA22E0984DQ39499575-BF061E95-46FA-4C9C-9004-300EEA943E74Q39503304-BF449905-1A6A-4670-A40C-880EE8A94B81Q39668604-33E95766-B056-4061-B6EB-272E017E022FQ39690297-82FDC820-ECC0-45DE-AE88-D93EE5C7F96DQ39743117-6BFDB82A-9C3D-49DD-BF96-60218A9470F3Q40146050-76CE2009-9E07-4D1D-ADF8-BE4228DBD49FQ40577241-27C18A67-F38A-4611-A5FE-B5A76D0E18A8Q41232445-383091E4-D3FF-46D8-9125-5D1879FDDD2CQ41619891-A10011FB-1546-47D9-A84B-25878765F8E4Q42158553-C2A4552B-73A5-4E65-B80B-E7099063CA74Q42731762-4C4C1F11-BE12-4884-A1B2-87CDA3E5D93DQ42746005-08076EB7-EEA3-45A0-9868-BF92F479F336Q42863482-961749C3-BFA0-4047-BA39-FF6236869E94Q42917410-771035B0-1596-4C7B-BD3B-B02CCF2F884C
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Stefano Alcaro
@ast
Stefano Alcaro
@en
Stefano Alcaro
@es
Stefano Alcaro
@nl
type
label
Stefano Alcaro
@ast
Stefano Alcaro
@en
Stefano Alcaro
@es
Stefano Alcaro
@nl
altLabel
Stefano ALCARO
@en
prefLabel
Stefano Alcaro
@ast
Stefano Alcaro
@en
Stefano Alcaro
@es
Stefano Alcaro
@nl
P106
P1153
6701804321
P21
P2798
P31
P496
0000-0002-0437-358X